Shareholder Tools

Press Releases

2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999
Press Releases
Date Title and Summary View
Jul 1, 2015 WEST LAFAYETTE, Ind., July 1, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the C...
May 13, 2015 WEST LAFAYETTE, Ind., May 13, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data featuring Endocyte's SMDC, EC1456 will be prese...
May 7, 2015 - Dose Escalation for EC1456 and EC1169 Move to Fifth Dosing Cohorts Evaluating Two Schedules for Each Agent - - Conference Call Today at 4:30 p.m. EDT - WEST LAFAYETTE, Ind., May 7, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging age...
Apr 30, 2015 WEST LAFAYETTE, Ind., April 30, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Thursday, May 7, at 4:30 p.m. EDT to discuss its first quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast of...
Apr 10, 2015 WEST LAFAYETTE, Ind., April 10, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that four posters will be presented by Endocyte scient...
Apr 7, 2015 WEST LAFAYETTE, Ind., April 7, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that P. David Mozley, M.D. has been appointed as vice pr...
Mar 20, 2015 WEST LAFAYETTE, Ind., March 20, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data from the PROCEED Study will be presented at t...
Mar 2, 2015 Dose Escalation Continues for EC1456 and EC1169 as Endocyte Outlines Plans for Expansion of the Trials in Targeted Patients Once Maximum Doses Are Determined Conference Call Today at 8:30 a.m. EST WEST LAFAYETTE, Ind., March 2, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug...
Feb 27, 2015 WEST LAFAYETTE, Ind., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data from ongoing phase 1 trials of Endocyte's SMD...
Feb 23, 2015 WEST LAFAYETTE, Ind., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Monday, March 2, at 8:30 a.m. EST to discuss its fourth quarter and full year 2014 financial results and provide an operational update. Investors and the general public are invited to listen t...
1
... NextLast
Add to Briefcase = add release to Briefcase